Skip to Main content Skip to Navigation
Journal articles

How can we best monitor 5-FU administration to maximize benefit to risk ratio?

Abstract : 5-Fluorouracil (5-FU) is currently used as a chemotherapy in several cancers such as head-and-neck (H&N) and colorectal cancers. 5-FU dosing is traditionally based on body surface area (BSA), but this strategy is usually associated with severe toxicities. 5-FU is mainly catabolized by dihydropyrimidine dehydrogenase (DPD), and 5-FU dosage adaptation according to DPD status at the first cycle of treatment is now recommended. To further optimize 5-FU-based chemotherapy, a body of evidences justifies therapeutic drug monitoring (TDM). Areas covered: 5-FU pharmacokinetics, relationships between pharmacokinetics and efficacy or toxicity of 5-FU, proofs of interest of 5-FU TDM and its practical considerations are discussed. Expert opinion: BSA-adjusted 5-FU administration is associated with a large inter-individual variability, and according to this strategy, many patients experience under- or overexposure. Moreover, relationships between 5-FU area under the curve (AUC) and its toxicity or efficacy have been demonstrated, at least in patients with colorectal or H&N cancers. 5-FU therapeutic index has been validated and algorithms of 5-FU dosage adaptation according to its AUC are now available. Advances in pre-analytical and analytical steps of 5-FU TDM make its use feasible in clinical practice. Thus, there are consistent evidences to recommend 5-FU TDM in patients with advanced colorectal or H&N cancers.
Document type :
Journal articles
Complete list of metadata

Cited literature [17 references]  Display  Hide  Download
Contributor : Laurent Jonchère <>
Submitted on : Friday, January 25, 2019 - 11:33:50 AM
Last modification on : Wednesday, May 26, 2021 - 8:08:03 PM


How can we best monitor 5FU ad...
Files produced by the author(s)



Françoise Goirand, Florian Lemaitre, Manon Launay, Camille Tron, Etienne Chatelut, et al.. How can we best monitor 5-FU administration to maximize benefit to risk ratio?. Expert Opinion on Drug Metabolism and Toxicology, Taylor & Francis, 2018, 14 (12), pp.1303-1313. ⟨10.1080/17425255.2018.1550484⟩. ⟨hal-01936325⟩



Record views


Files downloads